EUVIMEDEUVIMED entdecken
Crossref

Benefits and risks evaluation of recombinant human growth hormone replacement therapy in children with GHD after craniopharyngioma surgery

Li-Li Pei iD, Ying Guo, Han Chen iD, Li-Yong Zhong

Journal of Pediatric Endocrinology and Metabolism · 2023

DOI: 10.1515/jpem-2022-0605 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pediatric Endocrinology and Metabolism, 2023. Verfasst von Li-Li Pei und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Beijing Tiantan Hospital, Capital Medical University, Beijing, P.R. China. Hauptthemen laut MEDLINE: Craniopharyngioma, Human Growth Hormone, Dwarfism, Pituitary, Hypopituitarism. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Childhood-onset craniopharyngiomas (CPs) have a high incidence of growth hormone deficiency (GHD) leading to growth failure and metabolic disorders. We aim to evaluate the benefits and risks of recombinant human growth hormone replacement therapy (GHRT) in postoperative children.

Methods

We retrospectively analyzed auxological and metabolic parameters and adverse events before and after GHRT of 44 children after CP surgery.

Results

The median duration of GHRT was 24 months (IQR, 12.5–36). Growth velocity (GV) increased significantly after different treatment duration (TD) compared with baseline (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CraniopharyngiomaHuman Growth HormoneDwarfism, PituitaryHypopituitarismPituitary NeoplasmsHumansChildRetrospective StudiesNeoplasm Recurrence, LocalGrowth HormoneInsulin-Like Growth Factor IHormone Replacement TherapyRisk AssessmentGlucoseGrowth Disorders

Stichwörter der Autor:innen

childrencraniopharyngiomagrowth hormone deficiencyhuman growth hormone

Substanzen

Human Growth HormoneGrowth HormoneInsulin-Like Growth Factor IGlucose

Autor:innen und Institutionen

  • Department of Endocrinology, Beijing Tiantan Hospital, Capital Medical University, Beijing, P.R. China.

ORCID-Profile: Li-Li Pei, Han Chen

Zitieren

APA

Pei, L. L., Guo, Y., Chen, H., & Zhong, L. Y. (2023). Benefits and risks evaluation of recombinant human growth hormone replacement therapy in children with GHD after craniopharyngioma surgery. Journal of Pediatric Endocrinology and Metabolism. https://doi.org/10.1515/jpem-2022-0605

Vancouver

Pei LL, Guo Y, Chen H, Zhong LY. Benefits and risks evaluation of recombinant human growth hormone replacement therapy in children with GHD after craniopharyngioma surgery. Journal of Pediatric Endocrinology and Metabolism. 2023. doi:10.1515/jpem-2022-0605

BibTeX
@article{Pei2023,
  author = {Pei, Li-Li and Guo, Ying and Chen, Han and Zhong, Li-Yong},
  title = {Benefits and risks evaluation of recombinant human growth hormone replacement therapy in children with GHD after craniopharyngioma surgery},
  journal = {Journal of Pediatric Endocrinology and Metabolism},
  year = {2023},
  doi = {10.1515/jpem-2022-0605}
}
Kostenlos starten →